- Trials with a EudraCT protocol (34)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
34 result(s) found for: Behavior management.
Displaying page 1 of 2.
EudraCT Number: 2014-001157-17 | Sponsor Protocol Number: PSI-HAL-2014 | Start Date*: 2014-07-29 | |||||||||||
Sponsor Name:Fundació Parc Taulí | |||||||||||||
Full Title: Efficacy and safety of intranasal administration of haloperidol in agitated schizophrenic patients: a controlled, blinded, randomized and single-center clinical trial | |||||||||||||
Medical condition: Agitation in schizophrenic patients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004984-11 | Sponsor Protocol Number: P150962J | Start Date*: 2018-07-06 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: "Study of maintenance of the efficacy and adverse effects of pharmacological treatments in sex offenders with paraphilia" ESPARA | |||||||||||||
Medical condition: Sexual offenders with paraphilia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019930-28 | Sponsor Protocol Number: 31116 | Start Date*: 2011-03-09 | |||||||||||
Sponsor Name:Accare | |||||||||||||
Full Title: The effectiveness of Parent-Child Interaction Therapy versus methylphenidate in preschool children with ADHD and disruptive behavior problems with insufficient improvement through Parent Management... | |||||||||||||
Medical condition: ADHD ODD | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004299-20 | Sponsor Protocol Number: ELND005-AG201 | Start Date*: 2013-04-25 |
Sponsor Name:Transition Therapeutics Ireland Ltd | ||
Full Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheime... | ||
Medical condition: Agitation and Aggression in Moderate to Severe Alzheimer’s Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-021955-14 | Sponsor Protocol Number: BUP3030 | Start Date*: 2011-10-17 | ||||||||||||||||
Sponsor Name:Purdue Pharma L.P. | ||||||||||||||||||
Full Title: A Multicenter, Inpatient, Open-label Study to Characterize the Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Aged from Birth to 6 Years of Age... | ||||||||||||||||||
Medical condition: Acute moderate to severe pain requiring opioids for at least 24 hours in postoperative and prolonged endotracheal intubated patients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003556-31 | Sponsor Protocol Number: SHP-607-201 | Start Date*: 2015-02-10 |
Sponsor Name:Premacure AB, A Member of the Shire Group of Companies | ||
Full Title: Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care | ||
Medical condition: Retinopathy of Prematurity (ROP) | ||
Disease: | ||
Population Age: Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-000567-26 | Sponsor Protocol Number: 2010-021883-14 | Start Date*: 2013-01-31 | |||||||||||
Sponsor Name:Radboud University Medical Centre Nijmegen | |||||||||||||
Full Title: A randomized double-blind, placebo-controlled study of risperidone in the treatment of DSM-IV-TR conduct disorder in children and adolescents. | |||||||||||||
Medical condition: Conduct Disorder DSM-IV-TR; 312.8x¸ APA, 2000 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001916-37 | Sponsor Protocol Number: MATRICS_WP6-1 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:RADBOUD UNIVERSITY MEDICAL CENTER | |||||||||||||
Full Title: The neuropsychological characterization of aggressive behaviour in children and adolescents with Conduct Disorder or Oppositional Defiant Disorder (CD/ODD) | |||||||||||||
Medical condition: Aggressive behavior in children and adolescents with Conduct Disorder (CD) or Oppositional Defiant Disorder (ODD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000484-23 | Sponsor Protocol Number: NEFRTX1 | Start Date*: 2020-07-09 |
Sponsor Name:Vall d'Hebron Institute of Research | ||
Full Title: CHARACTERIZATION OF RITUXIMAB PHARMACOKINETICS IN PATIENTS WITH KIDNEY DISEASES WITH PRIMARY GLOMERULAR AFFECTATION | ||
Medical condition: KIDNEY DISEASES WITH PRIMARY GLOMERULAR AFFECTATION (glomerulonefritis membranosa, glomerulonefritis por cambios mínimos, vasculitis, glomerulosclerosis focal y segmentaria.) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2012-003560-49 | Sponsor Protocol Number: MD2012/01XP | Start Date*: 2012-10-11 | |||||||||||
Sponsor Name:Macarthys Laboratories Limited (trading as Martindale Pharma) | |||||||||||||
Full Title: A PHASE II, RANDOMISED, SINGLE CENTRE, OPEN-LABEL, TWO-ARM STUDY TO DETERMINE THE SAFETY AND EFFICACY OF BUPRENORPHINE ORAL LYOPHILISATE (XPRENOR ®) IN COMPARISON WITH BUPRENORPHINE SUBLINGUAL TABL... | |||||||||||||
Medical condition: Opioid dependency | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004671-39 | Sponsor Protocol Number: 2019/318 | Start Date*: 2020-01-28 |
Sponsor Name:Universitair Ziekenhuis Brussel (UZ Brussel) | ||
Full Title: The effect of handheld-multimedia versus midazolam premedication on the level of perioperative anxiety in pediatric day-care. A randomized controlled trial. | ||
Medical condition: Perioperative anxiety in children scheduled for an elective circumcision, dental care or tonsillectomy/adenoidectomy in day-care | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001839-77 | Sponsor Protocol Number: 5mille_CT1 | Start Date*: 2022-04-26 | |||||||||||
Sponsor Name:IRCCS MATERNO INFANTILE BURLO GAROFOLO | |||||||||||||
Full Title: A Multicentric, Drug-Repositioning, Self Controlled Case Series (SCCS) Clinical Trial to Evaluate the Efficacy and Safety of Perampanel in Improving Behavioral Symptoms and Increasing the Quality o... | |||||||||||||
Medical condition: Patients with POGZ related disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001832-23 | Sponsor Protocol Number: NEU_CH_7911 | Start Date*: 2013-10-23 | |||||||||||
Sponsor Name:Neurim Pharmaceuticals (1991) Ltd. | |||||||||||||
Full Title: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CIRCADIN® TO ALLEVIATE SLEEP DISTURBANCES IN CHILDREN WITH NEURODEVELOPMENTAL DISABILITIES | |||||||||||||
Medical condition: SLEEP DISTURBANCES IN CHILDREN WITH NEURODEVELOPMENTAL DISABILITIES | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA FI (Completed) GB (Completed) NL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005524-15 | Sponsor Protocol Number: ELND005-AG251 | Start Date*: 2013-09-03 |
Sponsor Name:Elan Pharma International Ltd | ||
Full Title: A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease. | ||
Medical condition: Agitation and Aggression in Moderate to severe Alzheimer's Disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-003791-13 | Sponsor Protocol Number: BP42992 | Start Date*: 2022-01-11 | |||||||||||
Sponsor Name:F. HOFFMANN - LA ROCHE LTD. | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF 52 WEEKS OF TREATMENT WITH BASMISANIL IN CHILDREN WITH DUP15... | |||||||||||||
Medical condition: Dup15q Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) PL (Completed) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002044-28 | Sponsor Protocol Number: HGT-MLD-070 | Start Date*: 2012-06-14 | |||||||||||
Sponsor Name:Shire Human Genetics Therapies Inc | |||||||||||||
Full Title: A Phase I/II, Multicenter, Open-label, Dose Escalation Study of HGT-1110 Administered Intrathecally in Children with Metachromatic Leukodystrophy | |||||||||||||
Medical condition: Treatment of Metachromatic Leukodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001210-25 | Sponsor Protocol Number: CIT-01 | Start Date*: 2008-05-27 | |||||||||||
Sponsor Name:National Institute of Allergy and Infectious Diseases (NIAID), NIH | |||||||||||||
Full Title: Open Randomized Multi-Center Study to Evaluate Safety and Efficacy of Low Molecular Weight Sulfated Dextran in Islet Transplantation. | |||||||||||||
Medical condition: Type 1 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002568-62 | Sponsor Protocol Number: AVB-PGRN-001 | Start Date*: 2023-03-13 |
Sponsor Name:AviadoBio Ltd | ||
Full Title: A Phase 1/2 Open-Label, Ascending Dose, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 Administered by Bilateral Intrathalamic Infusion in Subjects With Frontotemporal... | ||
Medical condition: Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) IT (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2008-004847-12 | Sponsor Protocol Number: RABGRD3004 | Start Date*: 2009-11-04 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Withdrawal Study to Evaluate the Safety and Efficacy of Delayed-Release Rabeprazole in 1- to 11-Month-Old Pediatric Subj... | |||||||||||||
Medical condition: Endoscopically proven gastroesophageal reflux disease (GERD) in a paediatric population of 1 to 11 month old subjects | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) NL (Completed) IT (Completed) BG (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005875-10 | Sponsor Protocol Number: VGFTe-ROP-2036 | Start Date*: 2022-03-10 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals. Inc. | |||||||||||||
Full Title: An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study | |||||||||||||
Medical condition: Retinopathy of prematurity (ROP) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Trial now transitioned) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
